The Cardioprotective Effects of 4-O-(2″-O-acetyl-6″-O- P-coumaroyl-β-Dglucopyranosyl)- P-coumaric Acid (4-ACGC) on Chronic Heart Failure

The 4-acgc isolated from bp was prepared to investigate the cardioprotective effects on attenuating chronic heart failure in-vivo and in-vitro. a chronic heart failure (chf) rat model was established to investigate the cardioprotective effects of 4-acgc. from this, several cardiac function indexes were recorded. the inflammatory markers including tumor necrosis factor-a (tnf-α), interleukin-6 (il-6), and interleukin-1ß (il-1ß) were evaluated by enzyme-linked immunosorbent assay (elisa). subsequently, serum levels of myocardial enzymes lactate dehydrogenase (ldh) and creatine kinase (ck) were also assessed by elisa kits. ultimately, the cardioprotective and anti-inflammatory effects of 4-acgc were further verified on cmecs. the results showed that the treatment of 4-acgc significantly reduced cardiac hypertrophy and reversed the ejection fraction (ef), heart rate (hr), fractional shortening (fs), and cardiac output (co) changes in chf rats. the treatment of 4-acgc could effectively inhibit the inflammatory cytokines induced by chf. it’s also showed that a reverse effect of 4-acgc on serum increased levels of ldh and ck in chf rats. the increased levels of il-1ß and il-6 stimulated by tnf-a on cmecs were also decreased after treating with 4-acgc. the present study provided experimental evidence that 4-acgc possessed obvious cardioprotective effects on attenuating chf. 4-acgc could suppress the expression of inflammatory mediators and myocardial enzymes, which might be one of the mechanisms.